by pulsepartner | Sep 9, 2026 | Blog Post
A recent Financial Times article, authored by Hugh Rienhoff, highlights a rising challenge for America’s life sciences ecosystem: as biotechnology fundraising has declined, venture capital (VC) investors are increasingly prioritizing later-stage drug candidates that...
by pulsepartner | Aug 26, 2026 | Innovations Advanced by M&A
This blog is another installment in a series, Innovations Advanced by M&A, that underscores the unique role of mergers and acquisitions in promoting a competitive and innovative life sciences ecosystem for patients. You can find previous blogs in this series here....
by pulsepartner | Aug 12, 2026 | Blog Post
A new BioSpace article highlights an urgent challenge: maintaining America’s leadership in developing rare disease treatments amid increasing global competition. Meeting that challenge will require policies that support the full life sciences innovation ecosystem –...
by pulsepartner | Jul 29, 2026 | Innovations Advanced by M&A
This blog is the latest installment in a series, Innovations Advanced by M&A, that underscores the unique role of mergers and acquisitions in promoting a competitive and innovative life sciences ecosystem for patients. You can find previous blogs in this series...
by pulsepartner | Jul 10, 2026 | Blog Post
PULSE continues to build awareness of the unique and fundamental role of life sciences mergers and acquisitions (M&A) and other pro-competitive partnerships. Read below for a round-up of recent PULSE updates and commentaries. Advocating for Balanced Competition...
by pulsepartner | Jul 2, 2026 | Blog Post
Policymakers in California, New York and across the country are considering state-level antitrust proposals that could chill innovation, competition and growth in key industries, including life sciences. The risk of misaligned state antitrust standards is especially...
